CyberCyte

CyberCyte, incorporated in the UK in February 2019 and based in Reading, England, sells an X-CTEM platform (CyberCyte X-Ray / CloudCyte) that unifies cyber asset attack surface management (CAASM), continuous threat exposure management, GRC automation, and digital forensic artifact analysis. The platform ingests asset and configuration data via agent and agentless methods, runs Automated Security Control Assessment (ASCA) to simulate attacks against existing controls, and maps findings to frameworks such as ISO 27001, NIST, and CIS, with a managed-service delivery model aimed partly at MSSPs.

The company lists enterprise customers including ENERJİSA, a Turkish energy distributor serving over ten million customers, and Dogus Group, a conglomerate of roughly 250 companies, alongside unnamed references to an international retailer and a Turkish bank with 500+ branches using its forensic module. It holds a 4.8-star rating on Gartner Peer Insights, though that rating rests on only four published reviews, a small sample that limits how much weight it can carry. The company appears to be bootstrapped or self-funded; no institutional venture round is publicly disclosed, and third-party directories estimate it at 11-50 employees.

Its differentiator is platform breadth — combining asset-level exposure visibility with GRC and forensic/threat-hunting capability in one product — rather than depth in any single discipline, positioning it as a consolidation play against point ASM and point GRC tools for mid-sized and MSSP-served organizations.